GlassScriptPhysician profile
Madai A Gomez
NPI 1447560446
$3,769.47
in general payments reported to CMS, 2019-2025
27 companies · $73.15 in 2025
The $73.15 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $1,216 · 2023: $1,710 · 2024: $439 · 2025: $73.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.50 | 2021-2025 | |
| Janssen Biotech, INC. | $518.82 | 2021-2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $503.61 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.99 | 2021-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $287.83 | 2021-2024 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $227.22 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $153.82 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $148.01 | 2021-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $110.95 | 2021-2023 | Suflave |
| Ironwood Pharmaceuticals, INC | $97.92 | 2022-2023 | Linzess |
| Merck Sharp & Dohme LLC | $95.15 | 2021-2023 | Dificid |
| Gilead Sciences, INC. | $74.26 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $66.40 | 2022-2023 | Clenpiq, Rebyota |
| Qol Medical, LLC | $59.98 | 2022-2023 | Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.94 | 2021-2023 | Avsola, Amjevita |
| Pfizer INC. | $44.45 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $42.32 | 2024 | |
| Boston Scientific Corporation | $36.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.33 | 2024 | Cyltezo |
| Genzyme Corporation | $22.79 | 2023 | |
| Csl Behring | $21.13 | 2022 | |
| Daiichi Sankyo INC. | $20.45 | 2021 | |
| Medtronic, INC. | $19.77 | 2023 | Interstim |
| Fresenius Kabi USA, LLC | $16.53 | 2023 | Idacio |
| Ardelyx, INC. | $16.23 | 2023 | Ibsrela |
| Lilly USA, LLC | $14.86 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madai Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.